Orthobiologics

The first patient has been treated in a multicenter study comparing Kuros Bioscience's MagnetOs bone graft substitute vs. autologous bone in...

Baxter was granted FDA 510(k) clearance to market ALTAPORE Bioactive Bone Graft as an autograft extender in posterolateral spinal fusion....

LifeNet Health commenced limited launch of PliaFX® Prime precision-engineered cortical fibers....

Synergy Biomedical received FDA 510(k) clearance to market BIOSPHERE® FLEX bone graft. ...

NuVasive commenced U.S. launch of three new biologic products for spine, including traditional bone allograft, an amniotic membrane and new...

Tobra Medical commenced U.S. launch of the Tobra Bone Basket to maximize collection of autograft bone....

Synergy Biomedical received FDA 510(k) clearance and commenced full launch of BIOSPHERE® MIS PUTTY for open, mini-open and percutaneous minimally invasive procedures....

Bone Therapeutics reported all patients met the primary endpoint in the U.S. Phase I/IIA study of ALLOB® allogeneic bone-cell therapy...

Baxter International received FDA 510(k) clearance for its Actifuse Flow bone graft substitute. ...

Histogenics' Phase III clinical trial of NeoCart® tissue engineered implant did not meet the primary endpoint of a statistically significant improvement in pain...